Genelux (GNLX) EV/FCF: History & Chart

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:31:33.520Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:31:33.520Z.

Quote observation: 2026-10-06T18:30:04.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 114,343,061
Total debt · period ending 2026-06-30: 2,420,000
Cash · period ending 2026-06-30: 9,184,000
TTM free cash flow · period ending 2026-06-30: -28,683,000

FMP input reference: 9a1dfb6c252c1cf241c11dff63bdf10e98668db23039cc4017602387c5996572

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

GNLX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

GNLX Competitors' EV/FCF Ratio

GNLX

Genelux Corporation

Current

Market Cap

$114.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCD

Lucid Diagnostics Inc.

vs GNLX

Market Cap

$114.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MXCT

MaxCyte, Inc.

vs GNLX

Market Cap

$114.08M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRBU

Caribou Biosciences, Inc.

vs GNLX

Market Cap

$114.88M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

UNCY

Unicycive Therapeutics, Inc.

vs GNLX

Market Cap

$113.07M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FHTX

Foghorn Therapeutics Inc.

vs GNLX

Market Cap

$112.42M

EV/FCF Ratio

N/A

TTM Avg

1.44x

3Y Avg

1.44x

5Y Avg

1.44x

AARD

Aardvark Therapeutics, Inc. Common Stock

vs GNLX

Market Cap

$109.86M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMDX

Insight Molecular Diagnostics Inc.

vs GNLX

Market Cap

$111.72M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COYA

Coya Therapeutics, Inc.

vs GNLX

Market Cap

$116.98M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LENZ

LENZ Therapeutics, Inc.

vs GNLX

Market Cap

$118.68M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Genelux Corporation (GNLX)	$114.34M	N/A	N/A	N/A	N/A
Lucid Diagnostics Inc. (LUCD)vs ›	$114.27M	N/A	N/A	N/A	N/A
MaxCyte, Inc. (MXCT)vs ›	$114.08M	N/A	N/A	N/A	N/A
Caribou Biosciences, Inc. (CRBU)vs ›	$114.88M	N/A	N/A	N/A	N/A
Unicycive Therapeutics, Inc. (UNCY)vs ›	$113.07M	N/A	N/A	N/A	N/A
Foghorn Therapeutics Inc. (FHTX)vs ›	$112.42M	N/A	1.44x	1.44x	1.44x
Aardvark Therapeutics, Inc. Common Stock (AARD)vs ›	$109.86M	N/A	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. (IMDX)vs ›	$111.72M	N/A	N/A	N/A	N/A
Coya Therapeutics, Inc. (COYA)vs ›	$116.98M	N/A	N/A	N/A	N/A
LENZ Therapeutics, Inc. (LENZ)vs ›	$118.68M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

GNLX EV/FCF Ratio Metrics

GNLX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics